<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pathophysiology of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> involves multiple mechanisms including neuroinflammation mediated by activated microglia and infiltrating macrophages/monocytes </plain></SENT>
<SENT sid="1" pm="."><plain>The present study employed a rat permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (pMCAO) model to study effects of <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) inhibition on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>, neuroinflammation, gene expression, and neurological deficits </plain></SENT>
<SENT sid="2" pm="."><plain>We found that post-pMCAO injections with HDAC inhibitors, <z:chebi fb="0" ids="39867">valproic acid</z:chebi> (VPA), <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> (SB), or <z:chebi fb="0" ids="46024">trichostatin A</z:chebi> (TSA), decreased brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="3" pm="."><plain>Postinsult treatment with VPA or SB also suppressed microglial activation, reduced the number of microglia, and inhibited other inflammatory markers in the ischemic brain </plain></SENT>
<SENT sid="4" pm="."><plain>The reduction in levels of acetylated <z:chebi fb="0" ids="15358">histone</z:chebi> H3 in the ischemic brain was prevented by treatment with VPA, SB, or TSA </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, injections with HDAC inhibitors superinduced heat-shock protein 70 and blocked pMCAO-induced down-regulation of phospho-Akt, as well as <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-elicited up-regulation of p53, inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase, and cyclooxygenase-2 </plain></SENT>
<SENT sid="6" pm="."><plain>The motor, sensory, and reflex performance of pMCAO rats was improved by VPA, SB, or TSA treatment </plain></SENT>
<SENT sid="7" pm="."><plain>The beneficial effects of SB and VPA in reducing brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological deficits occurred when either drug was administrated at least 3 h after ischemic <z:hpo ids='HP_0003674'>onset</z:hpo>, and the behavioral improvement was long-lasting </plain></SENT>
<SENT sid="8" pm="."><plain>Together, our results demonstrate robust neuroprotective effects of HDAC inhibitors against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-induced brain injury </plain></SENT>
<SENT sid="9" pm="."><plain>The neuroprotection probably involves multiple mechanisms including suppression of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced cerebral <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Given that there is no effective treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo>, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>